coli, which has been validated and licensed on a non-exclusive basis to leading pharmaceutical companies.įrançois Blondel, Chairman of the Board and CEO of Delphi Genetics, commented, “We are absolutely thrilled to team up with Catalent and, by combining with the companies it has already established in Belgium, create a European Center of Excellence in Cell and Gene Therapy. Under the terms of the agreement, Catalent will also acquire Delphi’s proprietary STABY ® technology, an antibiotic-free selection system for plasmid and protein production in E. Delphi has built a reputation for its ‘one-stop-shop’ capabilities that include process development, pilot production, plasmid design and production, strain screening and stability, and which span from preclinical to Phase 3 applications, using fully single-use technology. Its operations are headquartered at a 17,000-square-foot (1,600-square-meter) facility, adjacent to Catalent’s current cell therapy facilities. With these new services, Catalent’s fully integrated cell and gene offering will allow customers to de-risk and optimize their programs along the entire development pipeline.įounded in 2001 as a spin off from the Université libre de Bruxelles (ULB), Delphi Genetics is a leading bioproduction CDMO with capabilities in handling the entire plasmid DNA development and CGMP manufacturing process. Plasmid DNA is a key component in most gene therapy and gene-enabled cell therapy production processes. Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility.

and GOSSELIES, BELGIUM – February 23, 2021 - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

Delphi manufacturer